Advertisement

Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience

      Highlights

      • Diuretic resistance is a significant issue in acute heart failure.
      • Multisegment diuretic therapy with 4 diuretic classes lacks evidence for use.
      • Multisegment diuretic therapy increased diuretic response.
      • Multisegment diuretic therapy did not worsen kidney function or electrolytes.
      • Multisegment diuretic therapy requires prospective evaluation.

      Abstract

      Background

      The concept of multinephron segment diuretic therapy (MSDT) has been recommended in severe diuretic resistance with only expert opinion and case-level evidence. The purpose of this study was to investigate the safety and efficacy of MSDT, combining 4 diuretic classes, in acute heart failure (AHF) complicated by diuretic resistance.

      Methods and Results

      A retrospective analysis was conducted in patients hospitalized with AHF at a single medical center who received MSDT, including concomitant carbonic anhydrase inhibitor, loop, thiazide, and mineralocorticoid receptor antagonist diuretics. Subjects served as their own controls with efficacy evaluated as urine output and weight change before and after MSDT. Serum chemistries, renal replacement therapies, and in-hospital mortality were evaluated for safety. Patients with severe diuretic resistance before MSDT were analyzed as a subcohort. A total of 167 patients with AHF and diuretic resistance received MSDT. MSDT was associated with increased median 24-hour urine output in the first day of therapy compared with the previous day (2.16 L [0.95–4.14 L] to 3.08 L [1.74–4.86 L], P = .003) in the total cohort and in the Severe diuretic resistance cohort (0.91 L [0.43–1.43 L] to 2.08 L [1.13–3.96 L], P < .001). The median cumulative weight loss at day 7 or discharge was –7.4 kg (–15.3 to –3.4 kg) (P = .02). Neither serum sodium, chloride, potassium, bicarbonate, or creatinine changed significantly relative to baseline (P > .05 for all).

      Conclusions

      In an AHF cohort with diuretic resistance, MSDT was associated with increased diuresis without changes in serum chemistries or kidney function. Prospective studies of MSDT in AHF and diuretic resistance are warranted.

      Key Words

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ambrosy AP
        • Pang PS
        • Khan S
        • et al.
        Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial.
        Eur Heart J. 2013; 34: 835-843https://doi.org/10.1093/eurheartj/ehs444
        • Chioncel O
        • Mebazaa A
        • Maggioni AP
        • et al.
        Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry.
        Eur J Heart Fail. 2019; 21: 1228-1230https://doi.org/10.1002/ejhf.1492
        • Lala A
        • McNulty SE
        • Mentz RJ
        • et al.
        Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).
        Circ Heart Fail. 2015; 8: 741-748https://doi.org/10.1161/CIRCHEARTFAILURE.114.001957
        • Rubio-Gracia J
        • Demissei BG
        • Ter Maaten JM
        • et al.
        Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure.
        Int J Cardiol. 2018; 258: 185-191https://doi.org/10.1016/j.ijcard.2018.01.067
        • Felker GM
        • Ellison DH
        • Mullens W
        • Cox ZL
        • Testani JM
        Diuretic therapy for patients with heart failure: JACC state-of-the-art review.
        J Am Coll Cardiol. 2020; 75: 1178-1195https://doi.org/10.1016/j.jacc.2019.12.059
        • Cox ZL
        • Testani JM
        Loop diuretic resistance complicating acute heart failure.
        Heart Fail Rev. 2020; 25: 133-145https://doi.org/10.1007/s10741-019-09851-9
        • Mullens W
        • Damman K
        • Harjola VP
        • et al.
        The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology.
        Eur J Heart Fail. 2019; 21: 137-155https://doi.org/10.1002/ejhf.1369
        • Ellison DH
        • Felker GM
        Diuretic treatment in heart failure.
        N Engl J Med. 2017; 377: 1964-1975https://doi.org/10.1056/NEJMra1703100
        • Yancy CW
        • Jessup M
        • Bozkurt B
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 62: e147-e239https://doi.org/10.1016/j.jacc.2013.05.020
        • Hollenberg SM
        • Warner Stevenson L
        • Ahmad T
        • et al.
        2019 ACC Expert Consensus Decision Pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee.
        J Am Coll Cardiol. 2019; 74: 1966-2011https://doi.org/10.1016/j.jacc.2019.08.001
      1. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367:2296–304. doi:10.1056/NEJMoa1210357

        • Costanzo MR
        • Negoianu D
        • Jaski BE
        • et al.
        Aquapheresis versus intravenous diuretics and hospitalizations for heart failure.
        JACC Heart Fail. 2016; 4: 95-105https://doi.org/10.1016/j.jchf.2015.08.005
        • Brisco-Bacik MA
        • Ter Maaten JM
        • Houser SR
        • et al.
        Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis.
        J Am Heart Assoc. 2018; 7 (e publication ahead of print:e009149)e009149
        • Cox ZL
        • Hung R
        • Lenihan DJ
        • Testani JM
        Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T Trial.
        JACC Heart Fail. 2020; 8: 157-168https://doi.org/10.1016/j.jchf.2019.09.012
        • Testani JM
        • Brisco MA
        • Turner JM
        • et al.
        Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure.
        Circ Heart Fail. 2014; 7: 261-270https://doi.org/10.1161/CIRCHEARTFAILURE.113.000895
        • R Core Team
        R: A language and environment for statistical computing.
        R Foundation for Statistical Computing, Vienna, Austria2020 (Available from:)
        • Rao VS
        • Planavsky N
        • Hanberg JS
        • et al.
        Compensatory distal reabsorption drives diuretic resistance in human heart failure.
        J Am Soc Nephrol. 2017; 28: 3414-3424https://doi.org/10.1681/ASN.2016111178
        • Ter Maaten JM
        • Rao VS
        • Hanberg JS
        • et al.
        Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure.
        Eur J Heart Fail. 2017; 19: 1014-1022https://doi.org/10.1002/ejhf.757
        • ter Maaten JM
        • Valente MA
        • Damman K
        • Hillege HL
        • Navis G
        • Voors AA
        Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy.
        Nat Rev Cardiol. 2015; 12: 184-192https://doi.org/10.1038/nrcardio.2014.215
      2. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797–805. doi:10.1056/NEJMoa1005419

        • Kiernan MS
        • Stevens SR
        • Tang WHW
        • et al.
        Determinants of diuretic responsiveness and associated outcomes during acute heart failure hospitalization: an analysis from the NHLBI Heart Failure Network Clinical Trials.
        J Cardiac Fail. 2018; 24: 428-438https://doi.org/10.1016/j.cardfail.2018.02.002
      3. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013;310:2533–43. doi:10.1001/jama.2013.282190

        • Jermyn R
        • Rajper N
        • Estrada C
        • Patel S
        • Weisfelner Bloom M
        • Wadhwa NK
        Triple diuretics and aquaretic strategy for acute decompensated heart failure due to volume overload.
        Case Rep Cardiol. 2013; 2013750794https://doi.org/10.1155/2013/750794
        • Goyfman M
        • Zamudio P
        • Jang K
        • et al.
        Combined aquaretic and diuretic therapy in acute heart failure.
        Int J Nephrol Renovasc Dis. 2017; 10: 129-134https://doi.org/10.2147/IJNRD.S135660
        • Knauf H
        • Mutschler E
        Sequential nephron blockade breaks resistance to diuretics in edematous states.
        J Cardiovasc Pharmacol. 1997; 29: 367-372
        • Verbrugge FH
        • Dupont M
        • Bertrand PB
        • et al.
        Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload.
        Acta Cardiol. 2015; 70: 265-273https://doi.org/10.2143/AC.70.3.3080630
        • Verbrugge FH
        • Martens P
        • Ameloot K
        • et al.
        Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance.
        Eur J Heart Fail. 2019; 21: 1415-1422https://doi.org/10.1002/ejhf.1478
        • Rao VS
        • Ivey-Miranda JB
        • Cox ZL
        • et al.
        Natriuretic equation to predict loop diuretic response in patients with heart failure.
        J Am Coll Cardiol. 2021; 77: 695-708https://doi.org/10.1016/j.jacc.2020.12.022
      4. Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2009;2:370–6. doi:10.1161/CIRCHEARTFAILURE.108.821199

        • Butler J
        • Hernandez AF
        • Anstrom KJ
        • et al.
        Rationale and design of the ATHENA-HF trial: aldosterone targeted neurohormonal combined with natriuresis therapy in heart failure.
        JACC Heart Fail. 2016; 4: 726-735https://doi.org/10.1016/j.jchf.2016.06.003
        • Butler J
        • Anstrom KJ
        • Felker GM
        • et al.
        Efficacy and Safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial.
        JAMA Cardiol. 2017; 2: 950-958https://doi.org/10.1001/jamacardio.2017.2198
        • de Denus S
        • Leclair G
        • Dube MP
        • et al.
        Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.
        Eur J Heart Fail. 2020; 22: 1451-1461https://doi.org/10.1002/ejhf.1802
        • Patarroyo M
        • Wehbe E
        • Hanna M
        • et al.
        Cardiorenal outcomes after slow continuous ultrafiltration therapy in refractory patients with advanced decompensated heart failure.
        J Am Coll Cardiol. 2012; 60: 1906-1912https://doi.org/10.1016/j.jacc.2012.08.957
        • Cooper LB
        • Mentz RJ
        • Gallup D
        • et al.
        Serum bicarbonate in acute heart failure: relationship to treatment strategies and clinical outcomes.
        J Cardiac Fail. 2016; 22: 738-742https://doi.org/10.1016/j.cardfail.2016.01.007
        • Jentzer JC
        • DeWald TA
        • Hernandez AF.
        Combination of loop diuretics with thiazide-type diuretics in heart failure.
        J Am Coll Cardiol. 56. 2010: 1527-1534https://doi.org/10.1016/j.jacc.2010.06.034
        • Yancy CW
        • Jessup M
        • Bozkurt B
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 62: 1495-1539https://doi.org/10.1016/j.jacc.2013.05.019
        • Zheng H
        • Liu X
        • Sharma NM
        • Li Y
        • Pliquett RU
        • Patel KP
        Urinary proteolytic activation of renal epithelial NA+ channels in chronic heart failure.
        Hypertension. 2016; 67: 197-205https://doi.org/10.1161/HYPERTENSIONAHA.115.05838
        • Hughey RP
        • Carattino MD
        • Kleyman TR
        Role of proteolysis in the activation of epithelial sodium channels.
        Curr Opinion Nephrol Hypertens. 2007; 16: 444-450https://doi.org/10.1097/MNH.0b013e32821f6072
        • Zheng H
        • Liu X
        • Rao US
        • Patel KP
        Increased renal ENaC subunits and sodium retention in rats with chronic heart failure.
        Am J Physiol Renal Physiol. 2011; 300: F641-F649https://doi.org/10.1152/ajprenal.00254.2010
        • Loungani RS
        • Felker GM
        Is resistance futile? Addressing diuretic resistance during hospitalization for heart failure.
        JACC Heart Fail. 2020; 8: 169-171https://doi.org/10.1016/j.jchf.2019.10.008
        • Felker GM
        • Mentz RJ
        • Cole RT
        • et al.
        Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure.
        J Am Coll Cardiol. 2017; 69: 1399-1406https://doi.org/10.1016/j.jacc.2016.09.004
        • Griffin M
        • Rao VS
        • Ivey-Miranda J
        • et al.
        Empagliflozin in heart failure: diuretic and cardio-renal effects.
        Circulation. 2020; 142: 1028-1039https://doi.org/10.1161/CIRCULATIONAHA.120.045691
        • Damman K
        • Beusekamp JC
        • Boorsma EM
        • et al.
        Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
        Eur J Heart Fail. 2020; 22: 713-722https://doi.org/10.1002/ejhf.1713